Lanreotide Acetate · LANREOTIDE ACETATE 120 mg/.5mL · Injection · Subcutaneous · Cipla USA Inc.
NDC 69097-0906-67 · 1 POUCH in 1 CARTON / 1 SYRINGE in 1 POUCH / .5 mL in 1 SYRINGE · ANDA · View full market →
4 companies supply this market — a reasonable cushion if one runs into trouble. A Class II recall hit this product in the past year (Cipla USA, Inc.). One of its named manufacturing plants, Pharmathen International S.A., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Cipla USA Inc. | LANREOTIDE ACETATE 120 mg/.5mL | Jul 15, 2026 | Sep 3, 2026 |
| Cipla USA Inc. | LANREOTIDE ACETATE 90 mg/.3mL | Jul 15, 2026 | Sep 3, 2026 |
| Cipla USA Inc. | LANREOTIDE ACETATE 60 mg/.2mL | Jul 15, 2026 | Sep 3, 2026 |
| Exelan Pharmaceuticals, Inc. | LANREOTIDE ACETATE 120 mg/.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | LANREOTIDE ACETATE 90 mg/.3mL | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | LANREOTIDE ACETATE 60 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Ipsen Biopharmaceuticals, Inc. | LANREOTIDE ACETATE 60 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Ipsen Biopharmaceuticals, Inc. | LANREOTIDE ACETATE 120 mg/.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Ipsen Biopharmaceuticals, Inc. | LANREOTIDE ACETATE 90 mg/.3mL | Jul 15, 2026 | Sep 2, 2026 |
| Synergy Health AST, LLC | LANREOTIDE ACETATE 120 mg/.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Synergy Health AST, LLC | LANREOTIDE ACETATE 90 mg/.3mL | Jul 15, 2026 | Sep 2, 2026 |
| Synergy Health AST, LLC | LANREOTIDE ACETATE 60 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Lanreotide Acetate — NDC 69097-0906-67," retrieved September 3, 2026, https://drugdashboards.com/drug/69097090667.
Free to cite with attribution — see how the data is put together.